AKT1 and breast cancer: As they had previously found that mammary tumors treated with their Rac-specific inhibitor (EHop-016, which inhibits Rac activity through inhibiting the oncogenic GEF Vav [71]) showed an 85% decrease in surface blood vessels compared with vehicle-treated tumors [72], Castillo-Picardo and colleagues wanted to determine if EHop-016 inhibited angiogenesis.